Trials / Terminated
TerminatedNCT05909995
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Conditions
- Melanoma
- Hepatocellular Carcinoma (HCC)
- Renal Cell Carcinoma (RCC)
- Microsatellite Instability - High (MSI-H)
- Mismatch Repair Deficient (dMMR)
- Colorectal Carcinoma (CRC)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | INCB 99280 with Ipilimumab | Dose Escalation and expansion of INCB 99280 with Ipilimumab |
Timeline
- Start date
- 2023-08-29
- Primary completion
- 2024-09-19
- Completion
- 2024-11-11
- First posted
- 2023-06-18
- Last updated
- 2025-02-18
Locations
8 sites across 3 countries: United States, Canada, South Africa
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05909995. Inclusion in this directory is not an endorsement.